The inflammatory effect of cardiopulmonary bypass on leukocyte extravasation in vivo

Journal of Thoracic and Cardiovascular Surgery

Volumn 135, Issue 5, 2008, Pages 999-1006

  Evans, B J ^a   Haskard, D O ^b   Finch, J R ^a   Hambleton, I R ^c   Landis, R C ^c   Taylor, K M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CANTHARIDIN; CD11B ANTIGEN; L SELECTIN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BLISTER; CARDIOPULMONARY BYPASS; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; EXTRAVASATION; FEMALE; FLOW CYTOMETRY; HUMAN; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; MALE; NEUTROPHIL; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; BLISTER; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTES; MALE; MIDDLE AGED;

EID: 42949174653     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.08.071     Document Type: Article

References (34)

1. Day J.R.S., and Taylor K.M. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 3 (2005) 129-140
2. Kalman J., Juhasz A., Bogats G., Babik B., Rimanoczy A., Janka Z., et al. Elevated levels of inflammatory biomarkers in the cerebrospinal fluid after coronary artery bypass surgery are predictors of cognitive decline. Neurochem Int 48 (2006) 177-180
3. Ramlawi B., Rudolph J.L., Mieno S., Feng J., Boodhwani M., Khabbaz K., et al. C-reactive protein and inflammatory response associated to neurocognitive decline following cardiac surgery. Surgery 140 (2006) 221-226
4. Shann K.G., Likosky D.S., Murkin J.M., Baker R.A., Baribeau Y.R., DeFoe G.R., et al. An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg 132 (2006) 283-290
5. Clark W.M., Madden K.P., Rothlein R., and Zivin J.A. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke 22 (1991) 877-883
6. Mori E., del Zoppo G.J., Chambers J.D., Copeland B.R., and Arfors K.E. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke 23 (1992) 712-718
7. Day R.M., Harbord M., Forbes A., and Segal A.W. Cantharidin blisters: a technique for investigating leukocyte trafficking and cytokine production at sites of inflammation in humans. J Immunol Methods 257 (2001) 213-220
8. Honkanen R.E. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Lett 330 (1993) 283-286
9. Pierard-Franchimont C., and Pierard G.E. Cantharidin-induced acantholysis. Am J Dermatopathol 10 (1988) 419-423
10. Tromovitch T.A. Cantharadin. JAMA 215 (1971) 640
11. Moed L., Shwayder T.A., and Chang M.W. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol 137 (2001) 1357-1360
12. Philippidis P., Mason J.C., Evans B.J., Nadra I., Taylor K.M., Haskard D.O., et al. Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94 (2004) 119-126
13. Evans B.J., McDowall A., Taylor P.C., Hogg N., Haskard D.O., and Landis R.C. Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. Blood 107 (2006) 3593-3599
14. Gott J.P., Cooper W.A., Schmidt Jr. F.E., Brown III W.M., Wright C.E., Merlino J.D., et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 66 (1998) 747-753
15. Hill G.E., Alonso A., Spurzem J.R., Stammers A.H., and Robbins R.A. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110 (1995) 1658-1662
16. Wachtfogel Y.T., Kucich U., Hack C.E., Gluszko P., Niewiarowski S., Colman R.W., et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106 (1993) 1-9
17. Buziashvili Y.I., Ambat'ello S.G., Aleksakhina Y.A., and Pashchenkov M.V. Influence of cardiopulmonary bypass on the state of cognitive functions in patients with ischemic heart disease. Neurosci Behav Physiol 36 (2006) 107-113
18. Harmon D.C., Ghori K.G., Eustace N.P., O'Callaghan S.J., O'Donnell A.P., and Shorten G.D. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth 51 (2004) 1002-1009
19. Asimakopoulos G., Thompson R., Nourshargh S., Lidington E.A., Mason J.C., Ratnatunga C.P., et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 120 (2000) 361-369
20. Asimakopoulos G., Lidington E.A., Mason J., Haskard D.O., Taylor K.M., and Landis R.C. Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 122 (2001) 123-128
21. Pruefer D., Makowski J., Dahm M., Guth S., Oelert H., Darius H., et al. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg 75 (2003) 210-215
22. Anttila V., Hagino I., Iwata Y., Mettler B.A., Lidov H.G., Zurakowski D., et al. Aprotinin improves cerebral protection: evidence from a survival porcine model. J Thorac Cardiovasc Surg 132 (2006) 948-953
23. Asimakopoulos G., Kohn A., Stefanou D.C., Haskard D.O., Landis R.C., and Taylor K.M. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg 69 (2000) 1192-1197
24. Yagnik D.R., Evans B.J., Florey O., Mason J.C., Landis R.C., and Haskard D.O. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 50 (2004) 2273-2280
25. Kirkwood B.R., and Sterne J.A.C. Transformations. Essential medical statistics (2003), Blackwell Science, Oxford p. 118-28
26. Hill G.E., Pohorecki R., Alonso A., Rennard S.I., and Robbins R.A. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 83 (1996) 696-700
27. Nakamura K., Ueno T., Yamamoto H., Iguro Y., Yamada K., and Sakata R. Relationship between cerebral injury and inflammatory responses in patients undergoing cardiac surgery with cardiopulmonary bypass. Cytokine 29 (2005) 95-104
28. Alat I., Yuksel M., Buket S., Nalbantgil S., Askar F., Bayindir U., et al. The side-effects of cardiopulmonary bypass on the lungs: changes in bronchoalveolar lavage fluids. Perfusion 16 (2001) 121-128
29. Eppinger M.J., Jones M.L., Deeb G.M., Bolling S.F., and Ward P.A. Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res 58 (1995) 713-718
30. Rinder C.S., Rinder H.M., Johnson K., Smith M., Lee D.L., Tracey J., et al. Role of C3 cleavage in monocyte activation during extracorporeal circulation. Circulation 100 (1999) 553-558
31. Barone F.C., Arvin B., White R.F., Miller A., Webb C.L., Willette R.N., et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 28 (1997) 1233-1244
32. Levy J.H., Pifarre R., Schaff H.V., Horrow J.C., Albus R., Spiess B., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92 (1995) 2236-2244
33. Mangano D.T., Tudor I.C., and Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 354 (2006) 353-365
34. Mangano D.T., Miao Y., Vuylsteke A., Tudor I.C., Juneja R., Filipescu D., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 297 (2007) 471-479